Valion Bio, Inc. (VBIO)
| Market Cap | 1.09M -76.3% |
| Revenue (ttm) | n/a |
| Net Income | -19.23M |
| EPS | -210.20 |
| Shares Out | 887.59K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,726,056 |
| Open | 1.110 |
| Previous Close | 1.450 |
| Day's Range | 1.110 - 1.330 |
| 52-Week Range | 1.110 - 75.500 |
| Beta | 1.80 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About VBIO
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in Apr... [Read more]
Financial Performance
Financial StatementsNews
Valion, LarmorBio announces Velocity completed feasibility eval of BioScan-NMR
Valion Bio (VBIO) and LarmorBio announced that Velocity Bioworks, Valion’s wholly owned biologics contract development and manufacturing organization subsidiary, has successfully completed an initial ...
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
Velocity Bioworks successfully completes initial evaluation of LarmorBio's BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess...
Valion Bio highlights capabilities of Velocity Bioworks
Valion Bio (VBIO) highlighted the capabilities of its wholly owned contract development and manufacturing organization, CDMO, Velocity Bioworks. Velocity Bioworks is part of Valion’s own domestic biol...
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
Velocity Bioworks' San Antonio facility offers process development, analytical services, and early-phase clinical drug substance manufacturing for biotechnology companies evaluating U.S.-based product...
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers
Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹ Medical countermeasures need to scale al...
Valion Bio Registration statement: Registration filing
Valion Bio filed a registration statement on October 8, 2026, providing details about a securities offering with the SEC.
Valion Bio files $100M mixed securities shelf
06:06 EDT Valion Bio (VBIO) files $100M mixed securities shelf
Valion Bio outlines perspectives of new Board Chair Jensen
Valion Bio (VBIO) outlined the perspectives of its new Board Chair, Thomas Jensen, on advancing Entolimod. Entolimod is an investigational Toll-like receptor 5, TLR5, agonist being developed as a pote...
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data an...
Valion Bio Proxy statement: Proxy filing
Valion Bio filed a proxy statement on October 2, 2026, providing details for shareholder voting and corporate governance matters.
Valion Bio, Shear Kershman formulate oral mucosal entolimod
Valion Bio (VBIO) and Shear Kershman Laboratories announced the completion of formulation work under the companies’ ongoing program to develop a novel oral mucosal formulation of Entolimod, Valion’s i...
Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity
Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod program Next study will test whether the formulation delivers measurable amounts of Entolimod...
Valion Bio appoints Dean Zikria as interim CEO, Thomas Jensen as chair
Valion Bio (VBIO) announced decisive changes to its executive leadership team and Board of Directors. These leadership transitions are intended to strengthen organizational alignment and support focus...
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23, 2...
Valion Bio regains compliance with Nasdaq minimum bid price listing rule
Valion Bio (VBIO) has received formal written notification from The Nasdaq Stock Market confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing ...
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
Nasdaq confirms compliance with continued listing standard and closes the matter SAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion" or the "Company) anno...
Valion Bio appoints CFO Lisa Wolf as president, COO
Valion Bio (VBIO) announced strategic changes to its management team and Board of Directors designed to accelerate execution across its clinical and commercial initiatives and position the Company for...
Valion Bio Announces Changes to Management and Board of Directors
Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.
Valion Bio Inc trading halted, news pending
19:50 EDT Valion Bio (VBIO) Inc trading halted, news pending
Valion Bio announces 1-for-25 reverse stock split
Valion Bio (VBIO) announced that its Board of Directors has declared a 1-for-25 reverse stock split of the Company’s issued and outstanding shares of common stock. The purpose of the…
Valion Bio Announces Reverse Stock Split
SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock sp...
Valion Bio announces U.S. government-funded entolimod studies
Valion Bio (VBIO) announced that the Armed Forces Radiobiology Research Institute, under its contract with the National Institute of Allergy and Infectious Diseases, is conducting a U.S. Department of...
Valion Bio says Ukraine Ministry of Health accepts entolimod regulatory dossier
Valion Bio (VBIO) announced that Ukraine’s Ministry of Health has accepted the Company’s regulatory dossier for Entolimod for formal review under the country’s Regulatory Equivalence Pathway. Entolimo...
Valion Bio Quarterly report: Q2 2026
Valion Bio has published its Q2 2026 quarterly earnings report on August 14, 2026.
Valion Bio Transcript: EGM 2026
Shareholders considered two proposals: granting the Board authority for a reverse stock split and the ability to adjourn the meeting if needed. Both proposals received preliminary approval, with final results to be filed with the SEC.